文献速递免疫规划营养与食品安全

肠炎沙门菌保守抗原的鉴定及其交叉保护效率评价

Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.
PubMed 文献 · Vaccine · 2025-08-14

研究选取肠炎沙门菌OmpC、OmpD、OmpF、SseB和FliC五种保守抗原评价免疫保护效果,各抗原均诱导特异性体液和细胞免疫应答并降低死亡率与细菌负荷;SseB亚单位疫苗对同源肠炎沙门菌攻击生存率66.7%,对异源鼠伤寒沙门菌仅33.3%。

要点

  • 五种保守抗原均诱导特异性体液和细胞免疫应答,显著降低肠炎沙门菌攻击后死亡率和细菌负荷。
  • SseB亚单位疫苗对同源肠炎沙门菌攻击生存率66.7%,对异源鼠伤寒沙门菌攻击生存率33.3%。
  • SseB诱导部分针对沙门菌血清型的交叉反应性调理吞噬抗体应答。

核心结论

  • SseB是血清型特异性亚单位疫苗的关键候选抗原,为靶向保守毒力机制的多价疫苗策略奠定基础。

研究设计与样本

  • 研究选取肠炎沙门菌OmpC、OmpD、OmpF、SseB和FliC五种保守抗原,评价其免疫保护效果。

主要发现

  • 所有抗原均诱导针对各自抗原的强体液和细胞免疫应答,与感染对照相比显著降低肠炎沙门菌攻击后的死亡率和细菌负荷。
  • SseB亚单位疫苗诱导针对沙门菌血清型的部分交叉反应性调理吞噬抗体应答。
  • SseB保护效果呈血清型依赖:同源肠炎沙门菌攻击生存率66.7%,异源鼠伤寒沙门菌攻击生存率33.3%。
  • 两组均显示细菌定植显著减少且组织病理损伤减轻。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Salmonella, a major foodborne zoonotic pathogen, threatens global poultry production and public health. While inactivated vaccines exhibit limited efficacy and live attenuated vaccines raise safety concerns due to risks of virulence reversion, subunit vaccines represent a safer and more targeted alternative. However, existing subunit vaccines against Salmonella provide limited cross-serotype protection. To address this challenge, OmpC, OmpD, OmpF (outer membrane proteins), SseB (a Type III secretory system secretory protein), and FliC (flagellin) were selected as five conserved antigens of Salmonella Enteritidis (S. enteritidis) for evaluation of their immune protective efficacy in this work. Our data showed that all antigens exhibited strong humoral and cell-mediated immune responses specific to each antigen, significantly reducing mortality and bacterial burdens following S. enteritidis challenge compared to infected controls. Notably, the SseB subunit vaccine demonstrated promising but serovar-dependent protection, inducing partial cross-reactive opsonophagocytic antibody (OPA) responses against Salmonella serovars. Protection experiments revealed divergent efficacy: 66.7 % survival against homologous S. enteritidis versus limited 33.3 % survival against heterologous S. typhimurium challenge. Both groups exhibited significantly reduced bacterial colonization and mitigated histopathological damage. These findings position SseB as a key candidate for serovar-specific subunit vaccines, laying the groundwork for multivalent approaches targeting conserved virulence machinery.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Li G, Li Q, et al. Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis. Vaccine. 2025. PMID: 40815961. doi:10.1016/j.vaccine.2025.127622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。